Cure8 research brief
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric patients — including younger or lower-weight children — from IV to subcutaneous infliximab.
Pediatric patients with IBD and their parents/caregivers; pediatric gastroenterologists and clinicians managing biologic therapy; patients currently on IV infliximab or considering route-switching.
This abstract reports a single-center retrospective pediatric cohort of 20 IBD patients (ages 5–17) who transitioned from IV infliximab to subcutaneous infliximab (120 mg every other week). After a median follow-up of 44 weeks, 80% remained on subcutaneous therapy.
Serum infliximab concentrations rose after switching and most follow-up measurements hit the assay ceiling; pre-existing anti-infliximab antibodies became undetectable and no new antibodies were recorded. Two patients stopped therapy because of worsening paradoxical psoriasis; no other adverse events were reported.
The study is retrospective and relatively small but includes younger and lower-weight children and reports clinical persistence, pharmacokinetics, immunogenicity, and tolerability in real-world practice.
It suggests subcutaneous infliximab can be a feasible maintenance option, including early use after induction, while noting the need for pediatric-specific PK targets and individualized dosing. The source content depth is an abstract from the published article; the summary here reflects the abstract rather than a full-text review.
This is a single-center, retrospective cohort with 20 patients and limited follow-up; findings come from the article abstract. Larger prospective pediatric studies are needed to define dosing and pharmacokinetic targets. Two patients had worsening paradoxical psoriasis prompting discontinuation; other safety signals were limited in this small sample.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Ethics approval and consent to participate: This study was approved by the ethics committee of the Charité – Universitätsmedizin under EA2/094/25. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
